Indivior (NASDAQ:INDV) Director Acquires $27,427.25 in Stock

Indivior PLC (NASDAQ:INDV) Director Barbara Ryan bought 775 shares of the stock in a transaction dated Monday, January 5th. The stock was bought at an average cost of $35.39 per share, with a total value of $27,427.25. Following the purchase, the director owned 1,963 shares in the company, valued at $69,470.57. The trade was a 65.24% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Indivior Price Performance

INDV opened at $35.44 on Friday. The stock’s 50 day simple moving average is $34.16 and its 200 day simple moving average is $25.88. Indivior PLC has a 1 year low of $7.62 and a 1 year high of $38.00. The firm has a market cap of $4.43 billion, a price-to-earnings ratio of 38.52 and a beta of 0.75.

Indivior (NASDAQ:INDV) last announced its quarterly earnings data on Thursday, October 30th. The company reported $0.72 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.34. The firm had revenue of $314.00 million during the quarter, compared to the consensus estimate of $257.66 million. Indivior had a negative return on equity of 90.79% and a net margin of 9.83%. As a group, sell-side analysts anticipate that Indivior PLC will post 1.22 EPS for the current year.

Hedge Funds Weigh In On Indivior

Hedge funds and other institutional investors have recently modified their holdings of the stock. CWM LLC purchased a new stake in Indivior in the third quarter worth about $25,000. Quarry LP purchased a new position in shares of Indivior during the 3rd quarter worth approximately $26,000. Raymond James Financial Inc. bought a new position in shares of Indivior in the 2nd quarter worth approximately $26,000. GAMMA Investing LLC lifted its stake in shares of Indivior by 544.6% in the 4th quarter. GAMMA Investing LLC now owns 1,199 shares of the company’s stock valued at $43,000 after purchasing an additional 1,013 shares during the period. Finally, Plato Investment Management Ltd purchased a new position in shares of Indivior in the 3rd quarter valued at approximately $52,000. Hedge funds and other institutional investors own 60.33% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on INDV. Zacks Research upgraded shares of Indivior from a “hold” rating to a “strong-buy” rating in a research report on Monday, November 3rd. Northland Securities set a $40.00 target price on shares of Indivior in a report on Friday, October 31st. Piper Sandler reissued an “overweight” rating and issued a $41.00 target price (up from $27.00) on shares of Indivior in a research note on Friday, October 31st. HC Wainwright upped their price target on Indivior from $28.00 to $35.00 and gave the company a “buy” rating in a research report on Thursday, October 30th. Finally, Craig Hallum reiterated a “buy” rating and issued a $41.00 price objective on shares of Indivior in a report on Friday, October 31st. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $32.71.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.